TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17766429

Group type: EXPERIMENTAL
Intervention: SSV model for predicting 30-day survival
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: SSV model for predicting independent survival at 6 months
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: SSV model's ROC curve for 30-day survival
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: SSV model's ROC curve for independent survival at 6 months
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Calibration of the SSV model
Number of subjects: 537
Study: 15530588

Group type: EXPERIMENTAL
Intervention: Smoking reduction intervention
Number of subjects: 2408

Group type: EXPERIMENTAL
Intervention: High-intensity intervention (smoking reduction groups)
Number of subjects: 2408

Group type: COMPARATOR
Intervention: Background population (control)
Number of subjects: 2408

Group type: COMPARATOR
Intervention: Non-participants (assumed control)
Number of subjects: 2408

Group type: EXPERIMENTAL
Intervention: Reduction of at least 5 g
Number of subjects: 2408

Group type: EXPERIMENTAL
Intervention: Halving of tobacco consumption
Number of subjects: 2408
Study: 12180276

Group type: EXPERIMENTAL
Intervention: Topiramate (50-300 mg/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Bupropion SR (100-400 mg/day)
Number of subjects: 36
Study: 12417161

Group type: EXPERIMENTAL
Intervention: Moist Exposed Burn Ointment (MEBO) application
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional closed methods
Number of subjects: 0
Study: 9666536

Group type: EXPERIMENTAL
Intervention: Targeted low-dose warfarin (INR 1.5-2.0)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care plus placebo
Number of subjects: 0
Study: 8582151

Group type: EXPERIMENTAL
Intervention: Active antiplatelet regimens (including aspirin)
Number of subjects: 769

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 769
Study: 2765346

Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vecuronium
Number of subjects: 20
Study: 950457

Group type: EXPERIMENTAL
Intervention: Outplacement planning
Number of subjects: 84

Group type: COMPARATOR
Intervention: Inpatient care
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Outplacement planning (released)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Outplacement planning (not released)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Inpatient planning (not released)
Number of subjects: 84
Study: 31550951

Group type: EXPERIMENTAL
Intervention: Video laryngoscope-guided lightwand (Group VL)
Number of subjects: 318

Group type: COMPARATOR
Intervention: Single lightwand (Group L)
Number of subjects: 318
Study: 28579423

Group type: EXPERIMENTAL
Intervention: Serum phosphorus levels
Number of subjects: 3138

Group type: EXPERIMENTAL
Intervention: Serum phosphorus levels (without kidney measures)
Number of subjects: 3138
Study: 25714602

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EAC)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acupuncture (AC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: SHAM acupuncture
Number of subjects: 60
Study: 23691833

Group type: EXPERIMENTAL
Intervention: Instructional aids designed with human factors principles
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard manufacturer-provided visual aids (Control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Instructional aids
Number of subjects: 60
Study: 21787508

Group type: EXPERIMENTAL
Intervention: Taper 0.04
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Taper 0.06
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Taper 0.08
Number of subjects: 45
Study: 19338452

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 microg/d)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Strontium ranelate (2 g/d)
Number of subjects: 79
Study: 16777382

Group type: EXPERIMENTAL
Intervention: Povidone-iodine (1%, w/v)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 50
Study: 15085362

Group type: EXPERIMENTAL
Intervention: CETP/C-629A polymorphism (A-allel carriers)
Number of subjects: 1968

Group type: EXPERIMENTAL
Intervention: CETP genotypes
Number of subjects: 1968

Group type: EXPERIMENTAL
Intervention: CETP/C-629A polymorphism
Number of subjects: 1968

Group type: COMPARATOR
Intervention: Adjustment for classical risk factors
Number of subjects: 1968

Group type: COMPARATOR
Intervention: Controlling for HDL concentration
Number of subjects: 1968
Study: 11213861

Group type: EXPERIMENTAL
Intervention: Education program addressing breast cancer screening schedules and modalities, including training on breast self-examination (BSE), clinical breast examination (CBE), and mammography.
Number of subjects: 140
Study: 9299674

Group type: EXPERIMENTAL
Intervention: Decision-making strategy A (combination of disease indices and serum concentrations of orosomucoid)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Decision-making strategy B (disease indices only)
Number of subjects: 88
Study: 8117512

Group type: EXPERIMENTAL
Intervention: Flat A1 osteotomy (OT)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Steep A1 osteotomy (OT)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: A2 osteotomy with partial defect
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Reversed intertrochanteric osteotomy (OT)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Reversed subtrochanteric osteotomy (OT)
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: A2 osteotomy with complete medial defect using gamma nail
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: A2 osteotomy with complete medial defect using DHS after valgisating displacement OT
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: Subtrochanteric resection and double plate compound osteosynthesis (DPCO)
Number of subjects: 301

Group type: COMPARATOR
Intervention: Control group (no OT)
Number of subjects: 301
Study: 2874128

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Alprazolam
Number of subjects: 60

Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 60
Study: 31101513

Group type: EXPERIMENTAL
Intervention: Co-treatment with buspirone and AAPDs
Number of subjects: 200

Group type: COMPARATOR
Intervention: Monotherapy with AAPDs
Number of subjects: 200
Study: 28239942

Group type: EXPERIMENTAL
Intervention: Extended CBT (E-CBT)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Non-extended CBT (no additional CBT sessions)
Number of subjects: 219
Study: 25662346

Group type: EXPERIMENTAL
Intervention: Monofilament Test
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Motricity Index
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Nine‐Hole Peg Test (NHPT)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Community Integration Questionnaire
Number of subjects: 105
Study: 23159547

Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 7141

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7141
Study: 21917244

Group type: EXPERIMENTAL
Intervention: Implicit causal inferences (implied by subsequent footage)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Replacement of the resulting flight of the ball with irrelevant video
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scrambling event segments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Different causal implication conditions
Number of subjects: 0
Study: 19187641

Group type: EXPERIMENTAL
Intervention: Rapid fluid expansion (Group I, n = 36) at a rate of 10-15 ml x kg(‐1) x h(‐1)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Controlled fluid expansion (Group II, n = 40) at a rate of 5-10 ml x kg(‐1) x h(‐1)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Rapid fluid expansion (Group I)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Controlled fluid expansion (Group II)
Number of subjects: 76
Study: 17202428

Group type: EXPERIMENTAL
Intervention: Real-time feedback display of movement; adaptation to three different rotations of feedback display; sequential adaptation process.
Number of subjects: 0
Study: 14722035

Group type: EXPERIMENTAL
Intervention: DPPE plus DOX
Number of subjects: 256

Group type: COMPARATOR
Intervention: DOX
Number of subjects: 256
Study: 11573597

Group type: EXPERIMENTAL
Intervention: Erythromycin 1 mg kg(‐1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.15 mg kg(‐1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 80
Study: 9756242

Group type: EXPERIMENTAL
Intervention: Aerobic training (all round activities) 3-4 times a week for six months
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Cycle ergometer training 3-4 times a week for six months
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 229
Study: 7848006

Group type: EXPERIMENTAL
Intervention: Prophylactic use of eubiotics (bifidumbacterin and lactobacterin)
Number of subjects: 44
Study: 2693499

Group type: EXPERIMENTAL
Intervention: Dilevalol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study: 30295168

Group type: EXPERIMENTAL
Intervention: Total Contact Casting (TCC)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Traditional Dressing (TD)
Number of subjects: 31
Study: 27974308

Group type: EXPERIMENTAL
Intervention: Problematic eating attitudes (ChEAT scores ≥85th percentile)
Number of subjects: 13557

Group type: EXPERIMENTAL
Intervention: Problematic eating attitudes (ChEAT scores ≥85th percentile) after controlling for BMI at age 6.5 y
Number of subjects: 13557
Study: 24002121

Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times daily for 9 months
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sibutramine 10 mg daily for 9 months
Number of subjects: 76
Study: 24251286

Group type: EXPERIMENTAL
Intervention: Education of husbands about cesarean and vaginal delivery
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group (no education provided)
Number of subjects: 88
Study: 21124833

Group type: EXPERIMENTAL
Intervention: Grey dots task (distraction with irrelevant grey dot)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Red dot task (detection of color change in grey dot)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard AB task (identifying two target letters)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Red dot task
Number of subjects: 0
Study: 18067498

Group type: EXPERIMENTAL
Intervention: New brochure addressing common donor concerns and suggesting specific coping strategies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standard blood center brochure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control brochure on healthy eating and exercise
Number of subjects: 0
Study: 17175797

Group type: EXPERIMENTAL
Intervention: Autologous sural nerve grafts
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vein conduit with interposition of a posterior interosseous nerve segment
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 14534392

Group type: EXPERIMENTAL
Intervention: Enhanced gender- and culturally specific intervention conditions
Number of subjects: 71

Group type: COMPARATOR
Intervention: NIDA standard condition
Number of subjects: 71
Study: 10779449

Group type: EXPERIMENTAL
Intervention: EPO (100 or 500 U/kg of body weight given intravenously)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 8622077

Group type: EXPERIMENTAL
Intervention: Radioimmunoguided surgery (RIGS) using iodine 125‐labeled monoclonal antibodies (MAbs) B72.3 (anti‐TAG72)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Radioimmunoguided surgery (RIGS) using iodine 125‐labeled monoclonal antibodies (MAbs) FO23C5 (anti‐carcinoembryonic antigen [CEA])
Number of subjects: 21
Study: 1548650

Group type: COMPARATOR
Intervention: Standard course
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Additional seminar on otoscopy
Number of subjects: 35
Study: 3914702

Group type: EXPERIMENTAL
Intervention: Piroxicam 20 mg/d
Number of subjects: 19

Group type: COMPARATOR
Intervention: Naproxen 500 mg twice a day
Number of subjects: 19
Study: 30855399

Group type: EXPERIMENTAL
Intervention: Etoricoxib
Number of subjects: 351
Study: 28873106

Group type: EXPERIMENTAL
Intervention: Salicylic acid 30% peel
Number of subjects: 12

Group type: COMPARATOR
Intervention: Pneumatic broadband light (PBBL)
Number of subjects: 12
Study: 27087092

Group type: EXPERIMENTAL
Intervention: TEST 500 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: REF® 500 mg
Number of subjects: 12
Study: 23793487

Group type: EXPERIMENTAL
Intervention: Mothers and Babies Course (MB) intervention
Number of subjects: 78

Group type: COMPARATOR
Intervention: Usual home visiting services (control)
Number of subjects: 78
Study: 22318492

Group type: EXPERIMENTAL
Intervention: High-dose oral desensitization protocol enabled with omalizumab (anti-IgE monoclonal antibodies)
Number of subjects: 0
Study: 19514438

Group type: EXPERIMENTAL
Intervention: PEA with intramuscular ketorolac
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PEA with intramuscular ketorolac and intravenous paracetamol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Continuous epidural analgesia (PEA)
Number of subjects: 100
Study: 18161500

Group type: EXPERIMENTAL
Intervention: Superordinate concepts
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basic-level concepts
Number of subjects: 0
Study: 14707874

Group type: EXPERIMENTAL
Intervention: Local diagnosis by pathologists at 22 participating institutions
Number of subjects: 2004

Group type: COMPARATOR
Intervention: Central diagnosis by study pathologists
Number of subjects: 2004

Group type: COMPARATOR
Intervention: Open surgical biopsies
Number of subjects: 2004
Study: 11410120

Group type: EXPERIMENTAL
Intervention: Oral combined hormone replacement therapy (HRT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 9229276

Group type: EXPERIMENTAL
Intervention: Verbal communication plus PDQ Patient Information File (PIF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Verbal communication only
Number of subjects: 0
Study: 8213507

Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin
Number of subjects: 0
Study: 3679646

Group type: EXPERIMENTAL
Intervention: Electrical stimulation at 50 Hz
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electrical stimulation at 2000 Hz
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electrical stimulation at 50 Hz and 2000 Hz
Number of subjects: 0
Study: 30690550

Group type: EXPERIMENTAL
Intervention: SIPsmartER intervention
Number of subjects: 117
Study: 29660936

Group type: EXPERIMENTAL
Intervention: Baseline ACE‐1 levels
Number of subjects: 56
Study: 27857014

Group type: COMPARATOR
Intervention: Self-efficacy promoting vestibular rehabilitation (S-VR) after 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-efficacy promoting vestibular rehabilitation (S-VR) after 8 weeks
Number of subjects: 0
Study: 24625934

Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Diclofenac sodium 100 mg
Number of subjects: 120
Study: 23084768

Group type: EXPERIMENTAL
Intervention: Block autogenous bone
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Particulate graft
Number of subjects: 17
Study: 20678235

Group type: EXPERIMENTAL
Intervention: Fried pre‐clinical disability screening tool
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Statistical models
Number of subjects: 471
Study: 18261392

Group type: EXPERIMENTAL
Intervention: Anticoagulation therapy (Acenocoumarol)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 49
Study: 16760270

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg/day
Number of subjects: 448

Group type: COMPARATOR
Intervention: Tamoxifen 20 mg/day
Number of subjects: 448
Study: 12829890

Group type: COMPARATOR
Intervention: Tac and steroids (control)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: TacSRL0.5 (0.5 mg SRL)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: TacSRL1 (1 mg SRL)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: TacSRL2 (2 mg SRL)
Number of subjects: 104
Study: 10880788

Group type: EXPERIMENTAL
Intervention: Subthreshold transcranial magnetic stimulation (TMS) delivered at 90% of resting motor evoked potential (MEP) threshold
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Priming TMS with the go-signal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Occipital priming stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: M1 stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (normals)
Number of subjects: 0
Study: 9048263

Group type: EXPERIMENTAL
Intervention: Acetylcholine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Bradykinin
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Reactive hyperaemia
Number of subjects: 22
Study: 1619073

Group type: EXPERIMENTAL
Intervention: Moderately potent corticosteroids
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Very potent corticosteroids
Number of subjects: 66

Group type: COMPARATOR
Intervention: Moderately potent corticosteroids with propylene glycol 25%
Number of subjects: 66
Study: 6542402

Group type: EXPERIMENTAL
Intervention: Praziquantel (40 mg/kg single dose)
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Integrated chemotherapy, sanitation improvement, and health education
Number of subjects: 736

Group type: COMPARATOR
Intervention: Control (only chemotherapy)
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: Test villages
Number of subjects: 736

Group type: COMPARATOR
Intervention: Control village
Number of subjects: 736
Study: 31914451

Group type: EXPERIMENTAL
Intervention: Aspirin (ASP)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Aspirin + Clopidogrel (ASP-CLO)
Number of subjects: 207
Study: 28600597

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 132

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 132
Study: 25903091

Group type: EXPERIMENTAL
Intervention: Plasma alkylresorcinol concentrations
Number of subjects: 182
Study: 25766724

Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Imatinib 400 mg once daily
Number of subjects: 0
Study: 22900932

Group type: EXPERIMENTAL
Intervention: Screening intervention (fasting plasma glucose measurement and referral to GP if FPG ≥ 6.1 mmol/L)
Number of subjects: 10609

Group type: COMPARATOR
Intervention: Control group (received written healthy lifestyle information)
Number of subjects: 10609
Study: 20733132

Group type: EXPERIMENTAL
Intervention: TCG (carboplatin plus paclitaxel plus gemcitabine)
Number of subjects: 1742

Group type: COMPARATOR
Intervention: TC (carboplatin plus paclitaxel)
Number of subjects: 1742
Study: 18937623

Group type: EXPERIMENTAL
Intervention: Topical diclofenac formulations (sodium lotion, lecithin or epolamine gel, patch or plaster)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical diclofenac formulations
Number of subjects: 0
Study: 15769238

Group type: EXPERIMENTAL
Intervention: Presentation of performance information with small numbers (e.g., absence rates of 2% vs. 5%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Presentation of performance information with large numbers (e.g., attendance rates of 98% vs. 95%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Changing the presentation format of performance information
Number of subjects: 0
Study: 12360152

Group type: EXPERIMENTAL
Intervention: Tezosentan
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 10094298

Group type: EXPERIMENTAL
Intervention: Multi-sensory stimulation (auditory, tactile, visual, and vestibular intervention) for 15 minutes, twice a day, five days a week, for four weeks during hospitalization
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 7538547

Group type: EXPERIMENTAL
Intervention: Combination therapy with zidovudine and L‐697,661
Number of subjects: 119

Group type: COMPARATOR
Intervention: L‐697,661 alone
Number of subjects: 119

Group type: COMPARATOR
Intervention: Zidovudine alone
Number of subjects: 119
Study: 2405619

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 2332

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2332

Group type: EXPERIMENTAL
Intervention: Propranolol and nonsmoking
Number of subjects: 2332

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 2332
Study: 6631566

Group type: EXPERIMENTAL
Intervention: Vitamin C (1 g orally once a day, five times a week for 20 weeks)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Zinc (60 mg as zinc gluconate once a day, five times a week for eight weeks)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (matched control group)
Number of subjects: 50
Study: 30316907

Group type: EXPERIMENTAL
Intervention: Oral contraceptive pill (OCP) - 35μg of ethinylestradiol plus 2mg of cyproterone acetate for 6 cycles (28 days each)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Metformin - 500mg administered twice daily for 6 months
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (placebo pills during OCP treatment)
Number of subjects: 101
Study: 28277151

Group type: EXPERIMENTAL
Intervention: Cogmed Working Memory Training (CWMT) followed by Behavioral Parent Training (BPT)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo version of CWMT followed by Behavioral Parent Training (BPT)
Number of subjects: 85
Study: 26822324

Group type: EXPERIMENTAL
Intervention: Sitagliptin
Number of subjects: 282

Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 282
Study: 23597077

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 22333484

Group type: EXPERIMENTAL
Intervention: efavirenz (EFV)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: atazanavir/ritonavir (ATV/r)
Number of subjects: 75
Study: 19823919

Group type: EXPERIMENTAL
Intervention: Animation-based video education
Number of subjects: 242

Group type: COMPARATOR
Intervention: Control video
Number of subjects: 242
Study: 16887862

Group type: EXPERIMENTAL
Intervention: NSAID treatment
Number of subjects: 0
Study: 16849624

Group type: EXPERIMENTAL
Intervention: Ziconotide administered intrathecally via continuous infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0